Search results
TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the...
Digital Journal· 3 days ago("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that its IFx ...
The Cancer Screenings Every Young Woman Should Get
AOL· 6 days agoYou were probably shocked when Catherine, Princess of Wales, announced that she had cancer. It’s true that cancer in young adults is very uncommon—only ...
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
Morningstar· 4 days agoGlobal licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3Prolonged survival in Study ...
Prairie Fare: Are you taking care of your skin?
The Bismarck Tribune· 3 days ago“I thought you were wearing white knee socks,” someone said.
HOOKIPA advances HPV cancer trial with FDA nod By Investing.com
Investing.com· 3 days ago(NASDAQ: HOOK), a clinical-stage biopharmaceutical company, has announced the final design for its...
EU approves BeiGene's tislelizumab for lung cancer By Investing.com
Investing.com· 5 days agoThe European Commission (EC) has granted approval to tislelizumab for the treatment of non-small ...
Federated Hermes Inc. Sells 54,824 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO)
ETF DAILY NEWS· 10 hours agoFederated Hermes Inc. decreased its stake in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO – Free Report) by 21.8% in the fourth quarter, according to the company in its most recent Form ...
TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the...
The Joplin Globe· 3 days ago("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that its IFx ...
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse...
ABC 26 New Orleans· 4 days agoPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced ...
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Morningstar· 6 days agoKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today ...